FDA’s Role in ASTs and Understanding CLSI Breakpoint Decisions

This on-demand webinar will help labs understand the FDA's recognition and identification process of breakpoints for antimicrobial susceptibility (AST) testing and the FDA interpretive Criteria Webpages.

Learning Objectives

1. Discuss how laboratories and AST device manufacturers need to be able to use up-to-date Susceptibility Test Interpretive Criteria (STIC) or breakpoints for the reports provided to physicians to inform appropriate treatment choices. 

2. Review how the identification of patients who have certain types of resistant bacteria is also essential for infection control practices.